Avoiding Menstruation: A Review of Health and Lifestyle Issues

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 49, Issue 3, 2004, Pages 162-174

  Henzl, Milan R ^a   Polan, Mary Lake ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Contraceptives, oral; Life style; Menstruation; Mifepristone; Seasonale

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; ESTROGEN; ESTRONE; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS LYNESTRENOL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETYNODIOL DIACETATE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; SEASONALE ULTRA LO; UNCLASSIFIED DRUG;

AMENORRHEA; BLEEDING; CLINICAL TRIAL; CONTRACEPTION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; DYSMENORRHEA; ENDOMETRIOSIS; ENDOMETRIUM BIOPSY; FEMALE; HEALTH STATUS; HORMONAL REGULATION; HUMAN; LIFESTYLE; LONG TERM CARE; MENSTRUAL CYCLE; MENSTRUATION; ORAL CONTRACEPTION; PREGNANCY RATE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT FAILURE;

CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LIFE STYLE; MENSTRUATION;

EID: 1642546523     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Anderson FD: Personal communication, 2003
2. Anderson FD: The safety and efficacy of Seasonale®, a novel 91-day extended oral contraceptive regimen. Obstet Gynecol (suppl) 2002;99:26
3. Barr Laboratories, Inc: FDA approves Barr's SEASONALE®, an extended-cycle oral contraceptive. Woodcliff Lake, New Jersey, BL, September 5, 2003; http://www.seasonale.com/press_release.asp; accessed September 8, 2003.
4. Blanchard K: Life without menstruation. The Obstetrician Gynaecologist 2003;5:34-37
5. Brown A, Cheng L, Lin S, et al: Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: A double-blind randomized control trial of 2-and 4-mg per day for 120 days. J Clin Endocrinol Metab 2002;87:63-70
6. Cachrimanidou AC, Hellberg D, Nilsson S, et al: Long-interval treatment regimen with a desogestrel-containing oral contraceptive. Contraception 1993;48:205-216
7. Choi W, Pai H, Kim K, et al: Iron deficiency anemia increases nitric oxide production in healthy adolescents. Ann Hematol 2002;81:1-6
8. Coutinho EM: Latin America's contributions to contraceptive development. Fertil Steril 1993;60:227-230
9. Coutinho EM, de Souza JC, Csapo AI: Reversible sterility induced by medroxyprogesterone injections. Fertil Steril 1966;17:261-266
10. Coutinho EM, Segal SJ: Is Menstruation Obsolete? How Suppressing Menstruation Can Help Women Who Suffer from Anemia, Endometriosis, or PMS. New York, Oxford University Press, 1999
11. Crook D: Cardiovascular implications of menstrual cycle irregularities. Gynaecol Forum 2003;8:10-13
12. de Valk B, Marx JJM: Iron, atherosclerosis and ischemic heart disease. Arch Intern Med 1999;159:1542-1548
13. de Voogd WS: Postponement of withdrawal bleeding with a monophasic oral contraceptive containing desogestrel and ethinylestradiol. Contraception 1991;44:107-112
14. Den Tonkelaar I, Oddens BJ: Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999;59:357-362
15. Edelman A: Menstrual nirvana: Amenorrhea through the use of continuous oral contraceptives. Curr Womens Health Rep 2002;2:434-438
16. Gladwell M: John Rock's error. New Yorker 2000;15:52-63
17. Goldzieher J: Personal communication, 2003
18. Greenblatt RB: A new clinical test for the efficacy of progesterone compounds. Am J Obstet Gynecol 1958;76:626-628
19. Greenblatt RB: Delay-of-menses test. Pac Med Surg 1966;74: 127-130
20. Hamerlynck JV, Vollebregt JA, Doornebos CM, et al: Postponement of withdrawal bleeding in women using low-dose combined oral contraceptives. Contraception 1987;35:199-205
21. Heindrichs WL: Prevention of endometriosis signs or symptoms. US patent #6 265393 B1, filed 1998, issued 2001
22. Henzl MR, Loomba P: Transdemal delivery of sex steroids for hormone replacement therapy and contraception: A review of principles and practice. J Reprod Med 2003;48:525-540
23. Howes PS, Zacharski LR, Sullivan J, et al: Role of stored iron in atherosclerosis. J Vasc Nurs 2000;18:109-114
24. Kaunitz MA: Menstruation: Choosing whether ... and when. Contraception 2000;62:277-284
25. Kistner RW: Use of newer progestins in the treatment of endometriosis. Am J Obstet Gynecol 1958;75:264-278
26. Kornaat H, Geerdink MH, Klitsie JW: The acceptance of a 7-week cycle with a modern low-dose oral contraceptive (Minulet). Contraception 1992;45:119-127
27. Kwiecien M, Edelman, Nichols AMD, et al: Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: A randomized trial. Contraception 2003;67:9-13
28. Loudon NB, Fozwell M, Potta DM, et al: Acceptability of an oral contraceptive that reduces the frequency of menstruation: The tri-cycle pill regimen. BMJ 1977;2:487-490
29. Martin E: Mead, menstruation, and biological reductionism. http://www.barnard.columbia.edu/sfonline/mead/martin.htm; accessed July 8, 2003
30. The medicalisation of health. http://www.healthlibrary.com/reading/sabala/politics.htm; accessed July 17, 2003
31. Miller L, Hughes JP: Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: A randomized trial. Obstet Gynecol 2003;101:653-661
32. Miller L, Notter KM: Menstrual reduction with extended use of combination oral contraceptive pills: Randomized controlled trial. Obstet Gynecol 2001;98:771-778
33. Neergaard L: FDA approves new birth-control pill. Associated Press, September 6, 2003, America on Line, Health News; accessed September 6, 2003
34. O'Grady K: "Is Menstruation Obsolete?" http://www.third-space.ca/articles/ogrady.htm; accessed August 15, 2003
35. Shah SV, Alam MG: Role of iron in atherosclerosis. Am J Kidney Dis 2003;41:S80-S83
36. Shakespeare J, Neve E, Hodder K: Is norethisterone a lifestyle drug? Results of database analysis. BMJ 2000;320: 291-294
37. Steinkampf PM, Traynor K, Love L, et al: Continuous combined oral contraceptives: Results of a randomized controlled trial. Fertil Steril (suppl 1) 2001;76:S20
38. Strassmann BI: The evolution of endometrial cycles and menstruation. Q Rev Biol 1996;71:181-220
39. Sulak PJ, Cressman BE, Waldrop E, et al: Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997;89:179-183
40. Sullivan JL: Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis. Am Heart J 2003;145:190-194
41. Sullivan JL: Iron and the sex difference in heart disease risk. Lancet 1981;1:1293-1294
42. Thomas SI, Ellertson C: Nuisance or natural and healthy: Should monthly menstruation be optional for women? Lancet 2000;355:922-924
43. Tietze K: Spontane und artefizielle Cyclusverschiebungen. Arch Gynaekol 1965;202:202-204
44. Van Jaarsveld H, Pool GF: Beneficial effects of blood donation on high density lipoprotein concentration and the oxidative potential of low density lipoprotein. Atherosclerosis 2002;161:395-402
45. Vercellini P, De Giorgi O, Mosconi P, et al: Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril 2002;77:52-61
46. Westhoff C, Kaunitz AM: An overview of menstruation. Female Patient (suppl) 2002;Apr:4-7
47. World Health Organization: Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: Norethindrone enanthate and medroxyprogesterone acetate: Final report. Contraception 1983;28:1-20
48. World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation: A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: 1. Contraceptive efficacy and side effects. Contraception 1986; 34:223-235
49. Zacharski LR, Chow B, Lavori PW, et al: The iron (Fe) and atherosclerosis study (FeAST): Pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease. Am Heart J 2000;139:337-345